Voice Therapy
Customize your policy alerts
Sign up for Aetna Policy 0646 alerts
Get alerted when Policy 0646 changes without checking for updates manually.
Monitor payer policy activity
This policy governs Aetna's coverage and medical necessity criteria for voice therapy services for members, including indications considered medically necessary, not medically necessary, experimental/investigational uses, and related coding. It affects providers delivering speech-language pathology and otolaryngology services.
No material clinical or coverage changes in this revision.
Coverage Criteria for Voice Therapy
Medically Necessary Indications
Covered when ANY of the following indications are present:
From policy medical necessity list.
Not Medically Necessary Indications
Not covered when ANY of the following indications are sole reason for therapy:
Maintenance and cosmetic uses explicitly not medically necessary; voice feminization/masculinization for transgender individuals considered cosmetic (chunk 4).
Experimental / Investigational
Considered experimental/investigational (effectiveness not established):
Listed as experimental/investigational in policy.
Coverage considerations and evidence tiers
Summary of evidence-based coverage stance
Cochrane review identified benefit for combined therapy (chunks 32,33).
Evidence limited; considered experimental/unproven in absence of higher-level trials (chunks 25,26).
Pedrosa RCT and systematic reviews report positive outcomes (chunks 34,33).
Randomized trial evidence supports post-glottic carcinoma therapy (chunk 29).
Diagnosis and management descriptions support therapy role (chunk 30).
Evidence summaries and clinical implications
Evidence synthesis conclusions and clinical inferences reported in the document:
Supports cautious use where clinically appropriate based on patient factors and therapist expertise.
Consider a primary trial of voice therapy before surgery in selected patients; evidence insufficient to define a standardized protocol (chunks 41,46).
Experimental evidence—further validation needed.
May be used as initial or adjunctive therapy; limited evidence.
Limited case reports inform management decisions.
Voice therapy is generally recommended as the preferred therapeutic option for pediatric VFNs, though higher-quality trials are needed (chunks 54,55).
Evidence for voice therapy in pediatric vocal fold nodules
Evidence summary relevant to coverage decisions
Authors call for further well-designed RCTs and standardized outcome measures (chunks 54,55,56).
Voice therapy used specifically to feminize a male-to-female transgender individual's voice or to masculinize a female-to-male transgender individual's voice is considered cosmetic and is not medically necessary.
Portable voice amplifiers or megaphones (e.g., voice amplifiers) are not considered covered durable medical equipment and therefore are not covered under this policy.
Interventions supported only by small, uncontrolled, pilot, or retrospective studies—such as many reports of manual circumlaryngeal therapy (MCT/CMT)—lack randomized controlled trial data and durability evidence; these approaches may be considered experimental/investigational or not covered until higher-quality controlled evidence is available.
The evidence is insufficient to recommend voice therapy as a general treatment for symptomatic benign vocal fold lesions (cysts, nodules, polyps). Some lesions (e.g., vocal cysts) are unlikely to be cured by voice therapy alone and controlled trials comparing therapy with no intervention are lacking, so voice therapy cannot be broadly endorsed as a definitive treatment for these lesions.
Included studies across reviews were heterogeneous in design and interventions and lacked standardized, validated outcome measures. This methodological heterogeneity limited comparability across studies and precluded pooled meta-analysis of results.
Maintenance voice therapy when the member's symptoms are not improving is considered not medically necessary. If no clinical benefit is appreciated after 4 weeks of voice therapy, the treatment plan should be re-evaluated and continued therapy without meaningful improvement is not considered medically necessary.
Voice training programs or therapeutic approaches requested for a specific indication that are not supported by controlled evidence, lack objective or validated outcome measures, or lack reported treatment fidelity may be considered not medically necessary or experimental for that requested indication.
Coding and Billing
| 31505-31592 | Laryngoscopy and laryngoplasty procedures (therapeutic) |
| 31611 | Construction of tracheoesophageal fistula and subsequent insertion of an alaryngeal speech prosthesis (e.g., voice button, Blom-Singer prosthesis) |
| 92521 | Evaluation of speech fluency |
| 92522 | Evaluation of speech sound production |
| 92523 | Evaluation of speech sound production with evaluation of language comprehension and expression |
| 92524 | Behavioral and qualitative analysis of voice and resonance |
| 92597 |
| G0153 | Services performed by a qualified speech-language pathologist in the home health or hospice setting, each 15 minutes |
| G0161 | Services performed by a qualified speech-language pathologist, in the home health setting, in the establishment or delivery of a safe and effective speech-language pathology maintenance program, each 15 minutes |
| S9128 | Speech therapy, in the home, per diem |
| L8510 | Voice amplifier |
| L8500 | Artificial larynx, any type |
| L8505 | Artificial larynx replacement battery / accessory, any type |
| L8507 | Tracheo-esophageal voice prosthesis, patient inserted, any type, each |
| L8509 | Tracheo-esophageal voice prosthesis, inserted by a licensed health care provider, any type |
| V5362 | Speech screening |
| V5363 | Language screening |
| D14.1 | Benign neoplasm of larynx [benign vocal fold lesions] |
| F44.4 | Conversion disorder with motor symptom or deficit [functional dysphonia] |
| G25.2 | Other specified forms of tremor [voice] |
| J38.00-J38.02 | Paralysis of vocal cords and larnyx |
| J38.1 | Polyp of vocal cord and larynx |
| J38.2 | Nodules of vocal cords |
| R49.0 | Dysphonia [functional dysphonia] |
| S19.83X+ | Other specified injuries of vocal cord |
| A15.5 | Tuberculous laryngitis |
| A36.2 | Laryngeal diphtheria |
| A52.73 | Symptomatic late syphilis of other respiratory organs |
| A69.1 | Other Vincent's infections [Vincent's angina] |
| F64.1 | Gender identity disorder in adolescences and adulthood |
| J02.0 | Streptococcal pharyngitis |
| J04.0 | Acute laryngitis |
| No codes listed |
Provider Actions, Prior Authorization & Documentation
Prior authorization / coverage for primary voice therapy codes
CPT codes 92507 (individual voice therapy) and 92508 (group voice therapy) and specified home-health speech codes (e.g., G0153, G0161, S9128) are covered when the policy’s selection criteria are met; verify that the indication meets medical necessity before billing.
- 92507 — Treatment of speech, language, voice, communication, and/or auditory processing disorder; individual
- 92508 — Treatment of speech, language, voice, communication, and/or auditory processing disorder; group, two or more individuals
- G0153, G0161, S9128 — specified home-health/hospice speech therapy codes
Prior authorization may be needed for intensive or post‑surgical rehab
Prior authorization may be appropriate when voice therapy is requested as post-treatment rehabilitation after early glottic carcinoma or for prolonged/intensive manual circumlaryngeal therapy; include prior documentation of diagnosis and prior conservative measures.
- Include documentation of diagnosis and prior conservative measures when requesting authorization for intensive or post-surgical rehabilitation
- Evidence supports voice therapy for rehabilitation after early glottic carcinoma (van Gogh RCT)
No explicit additional prior authorization requirements specified
This policy excerpt does not specify any additional explicit prior authorization requirements or unique prior‑auth triggers beyond standard verification of medical necessity for voice therapy codes.
- No procedure‑specific prior authorization rules are listed in this section
Prior authorization (not specified in policy history excerpt)
The policy history and review notes in the document excerpt do not list specific procedure codes or explicit prior authorization statements; use plan-specific prior‑auth processes as applicable.
- Policy history shows last review 09/13/2023 and effective date 09/17/2002
Re‑evaluate therapy if no clinical benefit at 4 weeks
If no clinical benefit is observed after 4 weeks of voice therapy, re-evaluate the treatment plan; continued therapy without meaningful improvement may be denied as not medically necessary.
- Re-evaluate at 4 weeks; further therapy considered not medically necessary without meaningful improvement
- Maintenance treatment where symptoms are not improving is not medically necessary
Sequence conservative combined voice therapy before experimental or invasive options
Consider a trial of conservative voice therapy (combination of direct and indirect techniques) before proceeding to more invasive or experimental interventions when evidence supports it.
- Cochrane and systematic reviews support combined direct + indirect therapy versus no intervention
- Manual therapies have limited evidence and may be considered after conservative approaches
Step therapy consideration for benign vocal fold lesions (attempt voice therapy first in selected cases)
Some evidence and expert opinion suggest attempting voice therapy (pre‑operative or as primary treatment) for symptomatic benign vocal fold lesions may avoid surgery in selected cases; literature is heterogeneous and does not define a required step‑therapy protocol.
- Voice therapy may improve perceived voice quality and in some cases avoid surgery for benign vocal fold lesions
- No formal step‑therapy rules are specified in the policy
No formal step‑therapy rules specified
No formal step therapy rules are defined in this policy excerpt; clinical review sections summarize evidence for effectiveness but do not establish mandatory step protocols.
- Systematic reviews report heterogeneous evidence for pediatric vocal fold nodules and adult interventions
- Policy does not mandate a specific step‑therapy sequence
Perform otolaryngologic evaluation including laryngoscopy before/with therapy
An otolaryngologic evaluation (history, focused voice assessment and endoscopic laryngoscopy) is described as part of diagnosis and typical assessment prior to or alongside voice therapy.
- Otolaryngologist performs history, voice listening, and endoscopic (endoscope) visualization of vocal cords
- SLP assessments (e.g., acoustic spectrograph) may document voice strengths and weaknesses
Document diagnosis, prior treatments, objective and patient‑reported outcome measures
Document the diagnosis, prior treatments, objective measures and patient‑reported outcomes to support medical necessity for voice therapy requests and ongoing coverage decisions.
- Include diagnosis (e.g., MTD, UVFP, paradoxical vocal fold motion, BVFL), prior conservative treatments, and planned therapy type/number of sessions
- Provide objective and patient‑reported outcomes (VHI, V-RQOL, acoustic/perceptual measures) pre‑ and post‑therapy
Collect multi‑dimensional assessment documentation (VHI, VHI‑10, video‑stroboscopy, perceptual/acoustic ratings)
Use multi‑dimensional assessment protocols where available (self‑assessment scales such as VHI or VHI‑10, video‑stroboscopy, perceptual, aerodynamic and acoustic ratings) to document baseline status and response to therapy.
- Recommended measures referenced include VHI, VHI‑10, V-RQOL, videostroboscopy, perceptual and acoustic ratings
- Pre‑ and post‑therapy measurements strengthen documentation of clinical benefit
Voice feminization/masculinization for transgender individuals is not covered
Voice therapy to feminize male‑to‑female or masculinize female‑to‑male transgender individuals is considered cosmetic and is not covered; do not bill these services as medically necessary.
- Policy explicitly states these gender‑affirming voice therapy uses are not medically necessary
- Related CPB 0615 (Gender Affirming Surgery) referenced for context
Evidence limitations may lead to denial for experimental/unproven interventions
Interventions lacking controlled evidence, those supported only by small uncontrolled or pilot studies (e.g., many reports of manual circumlaryngeal therapy), or those without durable outcome data may be considered experimental/investigational and denied; include strong diagnostic and outcome documentation if requesting coverage.
- Manual laryngeal therapies have limited evidence and are often from small uncontrolled studies
- Policy classifies certain indications (pre‑operative therapy for benign lesions, chemotherapy‑related vocal fold motion impairment) as experimental/investigational
Denial risk for maintenance therapy without improvement after 4 weeks
If symptoms are unchanged after 4 weeks of therapy, continued maintenance therapy may be considered not medically necessary and subject to denial; document objective and patient‑reported lack of improvement when making coverage decisions.
- Maintenance treatment without improvement is not medically necessary
- Re‑evaluate and document outcomes at the 4‑week interval
Administrative note: CPBs guide but do not guarantee coverage
Clinical Policy Bulletins are administrative tools to assist benefit administration and do not themselves guarantee coverage; final coverage determinations remain subject to plan provisions.
- Use CPB guidance alongside plan benefit language when making coverage decisions
Background and Scope
Voice disorders such as vocal cord paralysis, benign lesions (nodules and polyps), and functional conditions like muscle tension dysphonia (MTD) can impair voice production and communication. Diagnosis typically involves an otolaryngologic evaluation including history, voice assessment, and laryngoscopic visualization. Treatment options include behavioral voice therapy (direct and indirect techniques), medical interventions, and surgery depending on etiology; for nodules, a typical conservative therapy course is often reported as approximately 6–10 sessions over 6–12 weeks.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.